drugset / Trial / NCT06994338
Tirzepatide for Alcohol Use Disorder
Phase 2
Recruiting
42 enrolled
University of Southern California
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Timeline
- Start
- 2025-10-06
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tirzepatide | Peptide | 2.5 mg | — |
| Subject | Tirzepatide | Peptide | 5 mg | — |